Manufacturer of Controlled Substances; Notice of Registration, 34040-34041 [E7-11916]

Download as PDF 34040 Federal Register / Vol. 72, No. 118 / Wednesday, June 20, 2007 / Notices Dated: June 7, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–11910 Filed 6–19–07; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Application Pursuant to Title 21 Code of Federal Regulations 1301.34(a), this is notice that on April 23, 2007, Cambrex Charles City, Inc., 1205 11th Street, Charles City, Iowa 50616–3466, made application by letter to the Drug Enforcement Administration (DEA) for registration as an importer of the basic classes of controlled substances listed in schedules II: Drug rwilkins on PROD1PC63 with NOTICES BILLING CODE 4410–09–P II II II DEPARTMENT OF JUSTICE Drug Enforcement Administration The company plans to import the listed controlled substances for manufacture of active pharmaceutical ingredients for sale to its customers. No comments, objections, or requests for any hearings will be received on any application for registration or reregistration to import crude opium, poppy straw, concentrate of poppy straw, and coca leaves. Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances listed in schedule I or II, which fall under the authority of section 1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B)) may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47. Any such comments or objections may be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537; or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 Jefferson-Davis Highway, Alexandria, 18:25 Jun 19, 2007 Dated: June 7, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–11915 Filed 6–19–07; 8:45 am] Schedule Thebaine (9333) ........................... Raw Opium (9600) ....................... Concentrate of Poppy Straw (9670). VerDate Aug<31>2005 Virginia 22301; and must be filed no later than July 20, 2007. This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR § 1301.34(b), (c), (d), (e) and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745), all applicants for registration to import a basic class of any controlled substances in schedule I or II are and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(b), (c), (d), (e) and (f) are satisfied. Jkt 211001 Importer of Controlled Substances; Notice of Application Pursuant to Title 21 Code of Federal Regulations 1301.34(a), this is notice that on May 16, 2006, Chattem Chemicals, Inc., 3801 St. Elmo Avenue, Building 18, Chattanooga, Tennessee 37409, made application by renewal to the Drug Enforcement Administration (DEA) for registration as an importer of the basic classes of controlled substances listed in schedule II: Drug Schedule Methamphetamine (1105) ............ Phenylacetone (8501) .................. Raw Opium (9600) ....................... Concentrate of Poppy Straw (9670). II II II II The company plans to import the listed controlled substances to manufacture bulk controlled substances for sale to its customers. No comments, objections, or requests for any hearings will be received on any application for registration or reregistration to import crude opium [Raw Opium (9600)], poppy straw, concentrate of poppy straw, and coca leaves. Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled PO 00000 Frm 00074 Fmt 4703 Sfmt 4703 substances listed in schedule I or II, which fall under the authority of section 1002(a)(2)(B) of the Act (21 U.S.C. 952(a)(2)(B) may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47. Any such comments or objections may be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537; or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 2401 Jefferson Davis Highway, Alexandria, Virginia 22301; and must be filed no later than July 20, 2007. This procedure is to be conducted simultaneously with and independent of the procedures described in 21 CFR § 1301.34(b), (c), (d), (e) and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745), all applicants for registration to import a basic class of any controlled substances in schedule I or II are and will continue to be required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(b), (c), (d), (e) and (f) are satisfied. Dated: June 7, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–11914 Filed 6–19–07; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration By Notice dated November 21, 2006, and published in the Federal Register on December 1, 2006, (71 FR 69593), Noramco Inc., 1440 Olympic Drive, Athens, Georgia 30601, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Oxymorphone (9652), a basic class of controlled substance listed in schedule II. E:\FR\FM\20JNN1.SGM 20JNN1 34041 Federal Register / Vol. 72, No. 118 / Wednesday, June 20, 2007 / Notices The company plans to manufacture for in-house dosage form production and for sales to other dosage form manufacturers. When the company first submitted their application, the company submitted information to DEA that the firm would be manufacturing Oxymorphone for in-house dosage form production and sales to other dosage form manufacturers. Upon further investigation by the DEA it was uncovered that the company would only be producing bulk material for dosage form manufacturers. DEA will grant this registration for the production of bulk manufacturing of Oxymorphone. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Noramco Inc. to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated Noramco Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed. Dated: June 7, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–11916 Filed 6–19–07; 8:45 am] BILLING CODE 4410–09–P Drug Enforcement Administration rwilkins on PROD1PC63 with NOTICES Manufacturer of Controlled Substances; Notice of Registration Jkt 211001 Lysergic acid diethylamide (LSD) (7315). 4-Methoxyamphetamine (7411) ... Normorphine (9313) ..................... Tetrahydrocannabinols (THC) (7370). Alphamethadol (9605) .................. Amphetamine (1100) .................... Methamphetamine (1105) ............ Cocaine (9041) ............................. Hydromorphone (9150) ................ Benzoylecgonine (9180) ............... Hydrocodone (9193) ..................... Morphine (9300) ........................... Oxycodone (9143) ........................ Meperidine (9230) ........................ Methadone (9250) ........................ Oxymorphone (9652) ................... I I I I I II II II II II II II II II II II The company plans to manufacture the listed controlled substances in bulk to manufacture controlled substance derivatives. These derivatives will be used in diagnostic products created specifically for internal use only. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Orasure Technologies, Inc. to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Orasure Technologies, Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. BILLING CODE 4410–09–P 63021–4500, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed in schedule I: Drug Marihuana (7360) ......................... Tetrahydrocannabinols (7370) ..... Schedule I I The company plans to import the above listed synthetic products for nonclinical laboratory based research only. In reference to drug code 7360 (Marihuana), the company plans to import synthetic cannabidiol. In reference to drug code 7370 (Tetrahydrocannabinols), the company plans to import synthetic THC. No other activity for this drug code is authorized for this registration. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Tocris Cookson, Inc. to import the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Tocris Cookson, Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed. Dated: June 7, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control,Drug Enforcement Administration. [FR Doc. E7–11912 Filed 6–19–07; 8:45 am] BILLING CODE 4410–09–P By Notice dated February 5, 2007, and published in the Federal Register on February 12, 2007, (72 FR 6579), Orasure Technologies, Inc., Lehigh University, Seeley G. Mudd-Building 6, 220 East First Street, Bethlehem, Pennsylvania 18015, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II: 18:25 Jun 19, 2007 Schedule Dated: June 7, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator,Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–11907 Filed 6–19–07; 8:45 am] DEPARTMENT OF JUSTICE VerDate Aug<31>2005 Drug DEPARTMENT OF JUSTICE DEPARTMENT OF LABOR Drug Enforcement Administration Office of the Secretary Importer of Controlled Substances; Notice of Registration By Notice dated March 19, 2007 and published in the Federal Register on March 27, 2007, (72 FR 14297), Tocris Cookson, Inc., 16144 Westwoods Business Park, Ellisville, Missouri PO 00000 Frm 00075 Fmt 4703 Sfmt 4703 Submission for OMB Review: Comment Request June 13, 2007. The Department of Labor (DOL) has submitted the following public information collection request (ICR) to E:\FR\FM\20JNN1.SGM 20JNN1

Agencies

[Federal Register Volume 72, Number 118 (Wednesday, June 20, 2007)]
[Notices]
[Pages 34040-34041]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-11916]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration

    By Notice dated November 21, 2006, and published in the Federal 
Register on December 1, 2006, (71 FR 69593), Noramco Inc., 1440 Olympic 
Drive, Athens, Georgia 30601, made application by letter to the Drug 
Enforcement Administration (DEA) to be registered as a bulk 
manufacturer of Oxymorphone (9652), a basic class of controlled 
substance listed in schedule II.

[[Page 34041]]

    The company plans to manufacture for in-house dosage form 
production and for sales to other dosage form manufacturers.
    When the company first submitted their application, the company 
submitted information to DEA that the firm would be manufacturing 
Oxymorphone for in-house dosage form production and sales to other 
dosage form manufacturers. Upon further investigation by the DEA it was 
uncovered that the company would only be producing bulk material for 
dosage form manufacturers. DEA will grant this registration for the 
production of bulk manufacturing of Oxymorphone.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a) and determined that the registration of 
Noramco Inc. to manufacture the listed basic class of controlled 
substance is consistent with the public interest at this time. DEA has 
investigated Noramco Inc. to ensure that the company's registration is 
consistent with the public interest. The investigation has included 
inspection and testing of the company's physical security systems, 
verification of the company's compliance with state and local laws, and 
a review of the company's background and history. Therefore, pursuant 
to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the above 
named company is granted registration as a bulk manufacturer of the 
basic class of controlled substance listed.

    Dated: June 7, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
 [FR Doc. E7-11916 Filed 6-19-07; 8:45 am]
BILLING CODE 4410-09-P